A Phase 1/2 interventional study of Nab-Paclitaxel and Gemcitabine in Pancreatic Adenocarcinoma, sponsored by Hoffmann-La Roche. Completed at 23 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A Phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC).
Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of patients who have received no prior systemic therapy for metastatic PDAC, and Cohort 2 will consist of patients who have received one line of prior systemic therapy for PDAC. In each cohort, eligible patients will be assigned to one of several treatment arms.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1: Participants will receive Nab-Paclitaxel 125 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle. Participants in the Cohort 1 control arm who experience disease progression will be given the option of enrolling into Cohort 2 (if open for enrollment), provided they meet eligibility criteria.
Drug: Nab-Paclitaxel · Drug: Gemcitabine
Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Selicrelumab 16 mg subcutaneous injection on Day 1 of Cycles 1-4 and every third cycle thereafter (i.e. Cycles 7, 10, 13 etc.) of each 28-day cycle.
Drug: Nab-Paclitaxel · Drug: Gemcitabine · Drug: Atezolizumab · Drug: Selicrelumab
Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Bevacizumab 10 mg/kg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
Drug: Nab-Paclitaxel · Drug: Gemcitabine · Drug: Atezolizumab · Drug: Bevacizumab
Cohort 1: Participant will receive AB928 150 mg orally once daily on Days 1 to 28 of each 28 day cycle; Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
Drug: Nab-Paclitaxel · Drug: Gemcitabine · Drug: Atezolizumab · Drug: AB928
Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Tiragolumab 420 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
Drug: Nab-Paclitaxel · Drug: Gemcitabine · Drug: Atezolizumab · Drug: Tiragolumab
Cohort 2: Participants will receive Cobimetinib 60 milligrams (mg) once daily orally on Days 1-21 of each 28-day cycle; and Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28-day cycle. Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arm is open for enrollment.
Drug: Atezolizumab · Drug: Cobimetinib
Cohort 2: Participants will receive PEGPH20 3 micrograms per kilogram (mcg/kg) IV infusion on Days 1, 8 and 15 of each 21-day cycle; and Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle. Participants who progressed on treatment, may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment.
Drug: Atezolizumab · Drug: PEGPH20
Cohort 2: Participants will receive BL-8040 1.25 milligrams per kilogram (mg/kg) subcutaneously (SC) on Days 1-5 of the first week, followed by combination treatment consisting of BL-8040 1.25 mg/kg SC three times a week on non-consecutive days and Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment.
Drug: Atezolizumab · Drug: BL-8040
Cohort 2: Participants will receive Atezolizumab 840 mg IV infusion on days 1 and 15 of each 28 day cycle; RO6874281 will be administered 10 mg by IV infusion on day 1 and 15 mg on days 8, 15, and 22 for cycle 1 (28 day cycle). RO6874281 will be administered 15 mg by IV infusion on days 1 and 15 of each subsequent 28 day cycle. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib, provided they meet the eligibility criteria and the arm is open for enrollment.
Drug: Atezolizumab · Drug: RO6874281
Cohort 2: Participants will receive Atezolizumab 1200 mg IV infusion on Day 1 of each 21 day cycle; and RO6874281 10 mg by IV infusion on day 1 of each 21 day cycle. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib, provided they meet the eligibility criteria and the arm is open for enrollment.
Drug: Atezolizumab · Drug: RO6874281
Cohort 2: Participants who progressed on a prior fluoropyrimidine-based regimen will receive Nab-paclitaxel 125 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle. Participants who progressed on a prior gemcitabine-based regimen will receive 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6). Participants will receive Oxaliplatin 85 mg/m\^2 IV on Days 1 and 15 of each 28 day cycle; Leucovorin 400 mg/m\^2 IV on Days 1 and 15 of each 28 day cycle; Fluorouracil 400 mg/m\^2 IV push on Days 1 and 15 of each 28 day cycle; and Fluorouracil 2400 mg/m\^2 IV continuous infusion over 46 hours on Days 1 and 2 and on Days 15 and 16 of each 28 day cycle. Participants who progressed on treatment, may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment.
Drug: Nab-Paclitaxel · Drug: Gemcitabine · Drug: Oxaliplatin · Drug: Leucovorin · Drug: Fluorouracil
Cohort 1: Participants will receive Tocilizumab 8 mg/kg IV infusion on Day 1 of each 28 day cycle; Atezolizumab 1680 mg IV infusion on Day 1 of each 28 day cycle; Nab-paclitaxel 125 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
Drug: Nab-Paclitaxel · Drug: Gemcitabine · Drug: Atezolizumab · Drug: Tocilizumab
Nab-Paclitaxel will be administered as per the schedule specified in the respective arm.
Gemcitabine will be administered as per the schedule specified in the respective arm.
Oxaliplatin will be administered as per the schedule specified in the respective arm.
Leucovorin will be administered as per the schedule specified in the respective arm.
Fluorouracil will be administered as per the schedule specified in the respective arm.
Atezolizumab will be administered as per the schedule specified in the respective arm.
Cobimetinib will be administered as per the schedule specified in the respective arm.
PEGPH20 will be administered as per the schedule specified in the respective arm.
BL-8040 will be administered as per the schedule specified in the respective arm.
Selicrelumab will be administered as per the schedule specified in the respective arm.
Bevacizumab will be administered as per the schedule specified in the respective arm.
RO6874281 will be administered as per the schedule specified in the respective arm
AB928 will be administered as per the schedule specified in the respective arm.
Tiragolumab will be administered as per the schedule specified in the respective arm.
Tocilizumab will be administered as per the schedule specified in the respective arm.
Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
OR was defined as a complete response (CR) or partial response (PR) on two consecutive occasions ≥ 4 weeks apart during Stage 1 as determined by the investigator using RECIST v.1.1. Objective response rate (ORR) was defined as the percentage of participants with OR. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. 95% confidence intervals (CI) for rates were constructed using Clopper-Pearson method. Percentages have been rounded off.
Time frame: Up to 33.3 months
Number of Participants With Adverse Events (AEs)
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.
Time frame: Up to 33.3 months
Stage 1: Progression-Free Survival (PFS), as Determined by Investigator According to RECIST v1.1
PFS was defined as the time from study treatment initiation to the first occurrence of documented PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurs first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum in the study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Kaplan-Meier (K-M) method was used to estimate PFS.
Time frame: Up to 33.3 months
Stage 1: Overall Survival (OS), as Determined by Investigator According to RECIST v1.1
OS was defined as the time from randomization to death from any cause. K-M method was used to estimate OS.
Time frame: Up to 33.3 months
Stage 1: OS Rate at Month 6
OS was defined as the time from randomization to death from any cause. OS rate at 6 months was defined as the percentage of participants who did not experience death from any cause at 6 months from randomization. K-M method was used to estimate OS. Percentages have been rounded off.
Time frame: Month 6
Stage 1: Duration of Response (DOR), as Determined by Investigator According to RECIST v1.1
DOR was defined as time from first occurrence of a documented OR until the time of documented PD or death from any cause, whichever occurs first as determined by investigator assessment using RECIST v1.1. DOR was calculated for participants who had a best confirmed OR of CR/PR. CR=the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to \<10 mm. PR=at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. PD=at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. K-M method was used to estimate DOR.
Time frame: Up to 33.3 months
Stage 1: Percentage of Participants With Disease Control (DC), as Determined by Investigator According to RECIST v1.1
DC was defined as stable disease (SD) for ≥ 12 weeks or a CR or PR, as determined by the investigator according to RECIST v1.1 Disease control rate (DCR) was defined as the percentage of participants with DC. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Percentages have been rounded off.
Time frame: Up to 33.3 months
A total of 341 participants with metastatic pancreatic ductal adenocarcinoma (PDAC) took part in the study from 05 Jul 2017 to 27 Feb 2025. The study included participants in 2 cohorts: Cohort 1: received no prior systemic therapy for metastatic PDAC \& Cohort 2: received 1 prior line of systemic therapy for PDAC. Multiple combination therapies were compared against common control(s) in Cohorts 1 and 2.
| Milestone | Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab | Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) | Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 2: Atezolizumab + BL-8040 | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + PEGPH20 | Stage 1 Cohort 2: Atezolizumab + RO6874281 Every 3 Weeks (Q3W) | Stage 1 Cohort 2: Atezolizumab + RO6874281 Every 2 Weeks (Q2W) | Stage 2 Cohort 2: Atezolizumab + Cobimetinib | Stage 2 Cohort 2: Atezolizumab + RO6874281 Q3W | Stage 2 Cohort 2: Atezolizumab + RO6874281 Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 35 | 9 | 25 | 16 | 42 | 31 | 25 | 25 | 16 | 15 | 71 | 16 | 15 | 0 | 0 | 0 |
| Safety population | 32 | 9 | 25 | 15 | 41 | 30 | 23 | 23 | 15 | 14 | 66 | 15 | 14 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 35 | 9 | 25 | 16 | 42 | 31 | 25 | 25 | 16 | 15 | 71 | 16 | 15 | 0 | 0 | 0 |
| Withdrew: Arm terminated by sponsor | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 22 | 8 | 23 | 14 | 34 | 28 | 19 | 21 | 14 | 10 | 59 | 14 | 14 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 1 | 0 | 0 | 1 | 0 | 1 | 2 | 2 | 0 | 1 | 3 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 3 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 0 | 1 | 0 | 2 | 0 | 3 | 2 | 2 | 4 | 9 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab | Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) | Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 2: Atezolizumab + BL-8040 | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + PEGPH20 | Stage 1 Cohort 2: Atezolizumab + RO6874281 Every 3 Weeks (Q3W) | Stage 1 Cohort 2: Atezolizumab + RO6874281 Every 2 Weeks (Q2W) | Stage 2 Cohort 2: Atezolizumab + Cobimetinib | Stage 2 Cohort 2: Atezolizumab + RO6874281 Q3W | Stage 2 Cohort 2: Atezolizumab + RO6874281 Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 6 | 1 |
| Safety population | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 6 | 1 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 6 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 4 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
OR was defined as a complete response (CR) or partial response (PR) on two consecutive occasions ≥ 4 weeks apart during Stage 1 as determined by the investigator using RECIST v.1.1. Objective response rate (ORR) was defined as the percentage of participants with OR. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. 95% confidence intervals (CI) for rates were constructed using Clopper-Pearson method. Percentages have been rounded off.
| percentage of participants | Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab | Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) | Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 2: Atezolizumab + BL-8040 | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + PEGPH20 | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | 37.5 (21.10 to 56.31) | 55.6 (21.20 to 86.30) | 48.0 (27.80 to 68.69) | 26.7 (7.79 to 55.10) | 31.7 (18.08 to 48.09) | 30.0 (14.73 to 49.40) | 8.7 (1.07 to 28.04) | 0 (0.00 to 14.82) | 0 (0.00 to 23.16) | 0 (0.00 to 23.16) | 6.1 (1.68 to 14.80) | 0 (0.00 to 21.80) | 7.1 (0.18 to 33.87) |
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.
| Participants | Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab | Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) | Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 2: Atezolizumab + BL-8040 | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + PEGPH20 | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W | Stage 2 Cohort 2: Atezolizumab + Cobimetinib | Stage 2 Cohort 2: Atezolizumab + RO6874281 Q3W | Stage 2 Cohort 2: Atezolizumab + RO6874281 Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | 32 | 9 | 24 | 15 | 41 | 30 | 22 | 23 | 15 | 14 | 65 | 15 | 14 | 14 | 6 | 0 |
PFS was defined as the time from study treatment initiation to the first occurrence of documented PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurs first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum in the study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Kaplan-Meier (K-M) method was used to estimate PFS.
| months | Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab | Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) | Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 2: Atezolizumab + BL-8040 | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + PEGPH20 | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 1: Progression-Free Survival (PFS), as Determined by Investigator According to RECIST v1.1 | 6.11 (5.13 to 9.92) | 4.04 (3.02 to 6.97) | 7.18 (5.03 to 9.82) | 8.21 (5.91 to 11.10) | 5.82 (4.40 to 7.52) | 5.39 (4.17 to 8.21) | 2.76 (1.45 to 5.52) | 2.53 (1.77 to 4.04) | 1.64 (1.41 to 1.87) | 1.28 (1.15 to 1.84) | 1.51 (1.38 to 2.56) | 1.38 (1.38 to 2.66) | 1.46 (1.31 to 1.58) |
OS was defined as the time from randomization to death from any cause. K-M method was used to estimate OS.
| months | Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab | Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) | Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 2: Atezolizumab + BL-8040 | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + PEGPH20 | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 1: Overall Survival (OS), as Determined by Investigator According to RECIST v1.1 | 14.55 (9.99 to 16.16) | 9.03 (3.42 to 16.13) | 13.34 (9.10 to 15.21) | 16.49 (9.59 to 19.71) | 13.34 (9.43 to 21.59) | 11.20 (8.21 to 17.94) | 6.77 (6.34 to 9.66) | 8.31 (4.11 to 13.04) | 4.47 (3.12 to 7.06) | 4.24 (1.84 to 6.97) | 7.06 (4.07 to 8.38) | 4.70 (3.81 to 11.04) | 7.33 (4.86 to 11.60) |
OS was defined as the time from randomization to death from any cause. OS rate at 6 months was defined as the percentage of participants who did not experience death from any cause at 6 months from randomization. K-M method was used to estimate OS. Percentages have been rounded off.
| percentage of participants | Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab | Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) | Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 2: Atezolizumab + BL-8040 | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + PEGPH20 | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 1: OS Rate at Month 6 | 87.07 (75.23 to 98.91) | 55.56 (23.09 to 88.02) | 83.48 (68.67 to 98.28) | 80.00 (59.76 to 100.00) | 72.55 (58.72 to 86.37) | 86.67 (74.50 to 98.83) | 78.76 (60.06 to 97.46) | 53.45 (30.72 to 76.19) | 27.78 (1.17 to 54.39) | 41.96 (14.01 to 69.91) | 51.97 (39.29 to 64.65) | 43.33 (17.35 to 69.32) | 50.00 (23.81 to 76.19) |
DOR was defined as time from first occurrence of a documented OR until the time of documented PD or death from any cause, whichever occurs first as determined by investigator assessment using RECIST v1.1. DOR was calculated for participants who had a best confirmed OR of CR/PR. CR=the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to \<10 mm. PR=at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. PD=at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. K-M method was used to estimate DOR.
| months | Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab | Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) | Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 2: Atezolizumab + BL-8040 | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + PEGPH20 | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 1: Duration of Response (DOR), as Determined by Investigator According to RECIST v1.1 | 5.40 (3.94 to 8.21) | 3.35 (2.56 to NA) | 8.18 (6.34 to 8.74) | 4.85 (2.86 to NA) | 4.47 (3.58 to 10.12) | 5.65 (4.53 to 10.84) | 3.37 (2.83 to NA) | — | — | — | 8.15 (5.32 to NA) | — | 6.14 (NA to NA) |
DC was defined as stable disease (SD) for ≥ 12 weeks or a CR or PR, as determined by the investigator according to RECIST v1.1 Disease control rate (DCR) was defined as the percentage of participants with DC. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Percentages have been rounded off.
| percentage of participants | Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab | Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) | Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 2: Atezolizumab + BL-8040 | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + PEGPH20 | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 1: Percentage of Participants With Disease Control (DC), as Determined by Investigator According to RECIST v1.1 | 81.3 (63.56 to 92.79) | 55.6 (21.20 to 86.30) | 64.0 (42.52 to 82.03) | 66.7 (38.38 to 88.18) | 61.0 (44.50 to 75.80) | 66.7 (47.19 to 82.71) | 30.4 (13.21 to 52.92) | 34.8 (16.38 to 57.27) | 0 (0.00 to 23.16) | 0 (0.00 to 23.16) | 18.2 (9.76 to 29.61) | 0 (0.00 to 21.80) | 7.1 (0.18 to 33.87) |
Collected over Up to 33.3 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) | 23/32 (71.9%) | 13/32 (40.6%) | 32/32 (100%) |
| Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab | 8/9 (88.9%) | 8/9 (88.9%) | 9/9 (100%) |
| Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab | 23/25 (92%) | 17/25 (68%) | 23/25 (92%) |
| Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 | 14/15 (93.3%) | 4/15 (26.7%) | 15/15 (100%) |
| Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab | 34/41 (82.9%) | 19/41 (46.3%) | 40/41 (97.6%) |
| Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab | 28/30 (93.3%) | 12/30 (40%) | 30/30 (100%) |
| Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) | 19/23 (82.6%) | 10/23 (43.5%) | 21/23 (91.3%) |
| Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) | 21/23 (91.3%) | 12/23 (52.2%) | 23/23 (100%) |
| Stage 1 Cohort 2: Atezolizumab + BL-8040 | 14/15 (93.3%) | 4/15 (26.7%) | 15/15 (100%) |
| Stage 1 Cohort 2: Atezolizumab + Cobimetinib | 11/14 (78.6%) | 8/14 (57.1%) | 13/14 (92.9%) |
| Stage 1 Cohort 2: Atezolizumab + PEGPH20 | 60/66 (90.9%) | 30/66 (45.5%) | 65/66 (98.5%) |
| Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W | 14/15 (93.3%) | 7/15 (46.7%) | 15/15 (100%) |
| Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W | 14/14 (100%) | 2/14 (14.3%) | 14/14 (100%) |
| Stage 2 Cohort 2: Atezolizumab + Cobimetinib | 14/14 (100%) | 7/14 (50%) | 13/14 (92.9%) |
| Stage 2 Cohort 2: Atezolizumab + RO6874281 Q3W | 5/6 (83.3%) | 2/6 (33.3%) | 6/6 (100%) |
| Stage 2 Cohort 2: Atezolizumab + RO6874281 Q2W | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) |
| Event | Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab | Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) | Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 2: Atezolizumab + BL-8040 | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + PEGPH20 | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W | Stage 2 Cohort 2: Atezolizumab + Cobimetinib | Stage 2 Cohort 2: Atezolizumab + RO6874281 Q3W | Stage 2 Cohort 2: Atezolizumab + RO6874281 Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 1/32 | 3/9 | 0/25 | 0/15 | 1/41 | 0/30 | 1/23 | 4/23 | 0/15 | 1/14 | 3/66 | 2/15 | 0/14 | 1/14 | 0/6 | 0/1 |
| Atrial fibrillationCardiac disorders | 0/32 | 2/9 | 0/25 | 0/15 | 0/41 | 0/30 | 1/23 | 0/23 | 0/15 | 0/14 | 0/66 | 0/15 | 0/14 | 0/14 | 0/6 | 0/1 |
| PneumoniaInfections and infestations | 2/32 | 2/9 | 0/25 | 0/15 | 3/41 | 1/30 | 0/23 | 0/23 | 1/15 | 0/14 | 0/66 | 0/15 | 0/14 | 1/14 | 0/6 | 0/1 |
| Abdominal painGastrointestinal disorders | 0/32 | 0/9 | 1/25 | 2/15 | 2/41 | 1/30 | 1/23 | 0/23 | 0/15 | 0/14 | 2/66 | 0/15 | 0/14 | 0/14 | 1/6 | 0/1 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/32 | 0/9 | 0/25 | 0/15 | 0/41 | 0/30 | 0/23 | 0/23 | 0/15 | 0/14 | 0/66 | 0/15 | 0/14 | 0/14 | 1/6 | 0/1 |
| Acute kidney injuryRenal and urinary disorders | 0/32 | 1/9 | 3/25 | 0/15 | 0/41 | 1/30 | 0/23 | 0/23 | 0/15 | 0/14 | 0/66 | 1/15 | 0/14 | 1/14 | 0/6 | 0/1 |
| Abdominal distensionGastrointestinal disorders | 0/32 | 1/9 | 0/25 | 0/15 | 0/41 | 0/30 | 0/23 | 0/23 | 0/15 | 0/14 | 0/66 | 0/15 | 0/14 | 0/14 | 0/6 | 0/1 |
| Retroperitoneal haemorrhageGastrointestinal disorders | 0/32 | 1/9 | 0/25 | 0/15 | 0/41 | 0/30 | 0/23 | 0/23 | 0/15 | 0/14 | 0/66 | 0/15 | 0/14 | 0/14 | 0/6 | 0/1 |
| ChillsGeneral disorders | 0/32 | 1/9 | 0/25 | 0/15 | 0/41 | 0/30 | 0/23 | 0/23 | 0/15 | 0/14 | 1/66 | 0/15 | 0/14 | 0/14 | 0/6 | 0/1 |
| Influenza like illnessGeneral disorders | 0/32 | 1/9 | 0/25 | 0/15 | 0/41 | 0/30 | 0/23 | 0/23 | 0/15 | 0/14 | 0/66 | 0/15 | 0/14 | 0/14 | 0/6 | 0/1 |
| Event | Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab | Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) | Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 2: Atezolizumab + BL-8040 | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + PEGPH20 | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W | Stage 2 Cohort 2: Atezolizumab + Cobimetinib | Stage 2 Cohort 2: Atezolizumab + RO6874281 Q3W | Stage 2 Cohort 2: Atezolizumab + RO6874281 Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 17/32 | 7/9 | 9/25 | 7/15 | 21/41 | 16/30 | 10/23 | 9/23 | 5/15 | 7/14 | 20/66 | 6/15 | 9/14 | 2/14 | 3/6 | 0/1 |
| Injection site reactionGeneral disorders | 0/32 | 4/9 | 0/25 | 0/15 | 0/41 | 0/30 | 0/23 | 0/23 | 11/15 | 0/14 | 1/66 | 0/15 | 0/14 | 0/14 | 0/6 | 0/1 |
| PyrexiaGeneral disorders | 11/32 | 5/9 | 3/25 | 3/15 | 14/41 | 2/30 | 1/23 | 5/23 | 2/15 | 5/14 | 7/66 | 7/15 | 10/14 | 2/14 | 3/6 | 0/1 |
| MyalgiaMusculoskeletal and connective tissue disorders | 4/32 | 4/9 | 3/25 | 0/15 | 5/41 | 5/30 | 1/23 | 2/23 | 0/15 | 0/14 | 45/66 | 0/15 | 2/14 | 0/14 | 0/6 | 0/1 |
| ChillsGeneral disorders | 0/32 | 3/9 | 2/25 | 0/15 | 5/41 | 0/30 | 0/23 | 1/23 | 0/15 | 1/14 | 1/66 | 10/15 | 6/14 | 1/14 | 2/6 | 0/1 |
| FatigueGeneral disorders | 18/32 | 5/9 | 11/25 | 3/15 | 23/41 | 7/30 | 5/23 | 9/23 | 10/15 | 5/14 | 21/66 | 5/15 | 6/14 | 2/14 | 2/6 | 0/1 |
| AnaemiaBlood and lymphatic system disorders | 14/32 | 4/9 | 10/25 | 9/15 | 13/41 | 6/30 | 4/23 | 6/23 | 3/15 | 2/14 | 8/66 | 1/15 | 1/14 | 3/14 | 2/6 | 0/1 |
| Neutrophil count decreasedInvestigations | 6/32 | 4/9 | 8/25 | 5/15 | 10/41 | 18/30 | 3/23 | 8/23 | 0/15 | 0/14 | 2/66 | 0/15 | 0/14 | 0/14 | 0/6 | 0/1 |
| Injection related reactionInjury, poisoning and procedural complications | 0/32 | 0/9 | 0/25 | 0/15 | 0/41 | 0/30 | 0/23 | 0/23 | 8/15 | 0/14 | 0/66 | 0/15 | 0/14 | 0/14 | 0/6 | 0/1 |
| Platelet count decreasedInvestigations | 4/32 | 3/9 | 4/25 | 4/15 | 11/41 | 16/30 | 2/23 | 4/23 | 0/15 | 0/14 | 1/66 | 4/15 | 1/14 | 0/14 | 0/6 | 0/1 |
Intent to treat (ITT) population included all randomized participants.
| Age, Customized(Participants) | Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab | Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) | Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 2: Atezolizumab + BL-8040 | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + PEGPH20 | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18-64 years | 15 | 6 | 13 | 11 | 26 | 11 | 9 | 20 | 8 | 9 | 49 | 8 | 8 | 193 |
| 65-84 years | 20 | 3 | 12 | 5 | 16 | 20 | 16 | 5 | 8 | 6 | 22 | 8 | 7 | 148 |
| Sex: Female, Male(Participants) | Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab | Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) | Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 2: Atezolizumab + BL-8040 | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + PEGPH20 | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 13 | 4 | 7 | 8 | 12 | 11 | 14 | 11 | 5 | 5 | 28 | 9 | 7 | 134 |
| Male | 22 | 5 | 18 | 8 | 30 | 20 | 11 | 14 | 11 | 10 | 43 | 7 | 8 | 207 |
| Ethnicity (NIH/OMB)(Participants) | Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab | Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) | Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 2: Atezolizumab + BL-8040 | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + PEGPH20 | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 | 0 | 5 | 0 | 0 | 1 | 0 | 0 | 3 | 0 | 1 | 12 |
| Not Hispanic or Latino | 33 | 9 | 23 | 16 | 36 | 30 | 25 | 24 | 16 | 15 | 68 | 16 | 14 | 325 |
| Unknown or Not Reported | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Race (NIH/OMB)(Participants) | Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab | Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) | Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) | Stage 1 Cohort 2: Atezolizumab + BL-8040 | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | Stage 1 Cohort 2: Atezolizumab + PEGPH20 | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W | Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 |
| Asian | 12 | 1 | 5 | 8 | 8 | 12 | 11 | 6 | 8 | 4 | 21 | 6 | 3 | 105 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Black or African American | 0 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 9 |
| White | 18 | 4 | 16 | 7 | 30 | 15 | 14 | 19 | 7 | 9 | 43 | 10 | 11 | 203 |
| More than one race | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 5 | 1 | 2 | 0 | 3 | 3 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2017 to primary completion in Feb 2025, 91 months.
Results were first posted in Nov 2025, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Albumin-Bound Paclitaxel · Gemcitabine · Cobimetinib · PEGPH20 · Motixafortide · Selicrelumab · Bevacizumab · Simlukafusp alfa · AB928 · Tiragolumab · Tocilizumab